In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.

Ai Ng SY., Zhu D., Herrington WG.

DOI

10.7326/ACPJ202002180-018

Type

Journal article

Journal

Ann Intern Med

Publication Date

18/02/2020

Volume

172

Keywords

Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Renal Insufficiency, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors

Permalink Original publication